Tracers / [131I]iodocarvedilol
[131I]iodocarvedilol
Also written as [I-131]iodocarvedilol
- Radionuclide
- I-131 t½ 11549 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- Carvedilol derivative (beta-blocker small molecule)
- Target / mechanism
- —
- Clinical application
- Potential radiopharmaceutical for heart (myocardial) imaging by SPECT PMID 36922888
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | 92.6 ± 2.77% | — | Carvedilol Memphis Pharmaceutical Company, Egypt | 36922888 2023 BMC Chem Under oxidative circumstances in the presence of CAT, [131I]iodocarvedilol was frequently produced via direct electrophilic substitution with no carrier added (NCA) 131I. — Carvedilol was labeled with iodine-131 at pH 6 with a labeling yield of 92.6 ± 2.77% by using 100 µg carvedilol, 200 µg chloramin-T (CAT) and 30 min reaction time. |
Need this precursor?We can point you to suppliers for [131I]iodocarvedilol, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36922888: 'Carvedilol was purchased from Memphis pharmaceutical company; Egypt and all other chemicals were purchased from Merck and they were analytical reagents.'.